About Hotgen

Approved:

Beijing Patent Pilot Enterprise;

Beijing high-tech enterprise.

Approved as Zhongguancun High-tech Enterprise.

China's first luminescence fully quantitative immunoassay analyzer - UPT and supporting reagents were successfully launched.

Top 100 high-growth enterprises in Zhongguancun

Approved as "Beijing Key Laboratory of Biological Emergency and Clinical POCT".

Beijing Biopharmaceutical G20 Enterprise;

Ranked first in Beijing’s high-tech achievements transformation biotechnology.

Sungen was established to focus on the research and development of antibody drugs.

Completed the development of new coronavirus detection kit in 45 days;

COVID-19 UPT antibody detection kit approved.

Nature published two articles:

GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia;

GP73 links SARS-CoV-2 infection with dysglycaemia.

"Extracellular vesicle extraction kit" and "fully automatic sample processing system" were authorized by the national invention patent;

Yugen was established to focus on the research and development of live bacterial drugs, intestinal microorganisms and various metabolic and immune diseases.

The fully automatic up-transfer luminescence immunoassay (UPT6800) won the APEC “Light of Innovation Innovation Outstanding Achievements Award”;

Antigen self-testing reagents have been approved in many countries such as the European Union and the United States, and have successively supported epidemic prevention and control in Hong Kong, France, the United Kingdom and other places.

Nature published an article:

Deficiency of ASGR1 promotes liver injury by increasing GP73-mediated hepatic

endoplasmic reticulum stress.

Self-developed sugar chain exosome GIyExo-Capture® technology platform;

Obtained Japanese PCT patent;

"2022 Private Science and Technology Development Contribution Award" First Prize for Science and Technology Innovation;

The world's first! Sungen’s myocardial infarction emergency antibody drug SGC001 received Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA).